

**AMENDMENT****In the Claims:**

B<sup>1</sup> ~~23.~~<sup>1</sup> (Amended) The compound 2-(2-amino-1,6-dihydro-6-oxo-purin-9-yl)methoxy-3-hydroxy-1-propanyl-L-valinate hydrochloride in crystalline form.

B<sup>2</sup> ~~25.~~<sup>3</sup> (Amended) A method of treating an animal infected with a [herpes viral infection] virus selected from herpes simplex virus and cytomegalovirus, comprising administering a therapeutically effective amount of the compound of Claim ~~23~~<sup>1</sup> to the animal.

**REMARKS**

Entry of the amendment is respectfully requested. No new matter is added by the amendment, because the amended claims are fully supported by the application as filed. In particular, the amendment to crystalline ganciclovir mono(L-valinate) hydrochloride (GMVH) is supported by Examples 3B and 4 (page 32), and the amendment to treatment of infection by herpes simplex virus and cytomegalovirus is supported by the disclosure at page 13, the paragraph at lines 13-27.

The amendment is made without prejudice to Applicants' right to pursue the unamended claims in a continuation application.

Claims 23-28 are in this application, no claims having been added or canceled, and Claims 23 and 25 having been amended in this Response. Claims 25-26 were rejected under 35 USC 112, ¶1; and Claims 23-28 were rejected under 35 USC 102(b) and 103(a). These rejections, as applied to the amended claims, are respectfully traversed.